Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 7/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931383 | 0.84 | CCNA2 (0.47) | HTTCNR1CNR2 | |
| SCHEMBL4930535 | 0.82 | ALDH1A1 (0.46) | HTTCNR2KMT2ALMNA | |
| SCHEMBL2826673 | 0.78 | KDM4E (0.52) | — | |
| SCHEMBL4934607 | 0.77 | HTT (0.46) | HTTCNR1CNR2LMNA | |
| SCHEMBL4933829 | 0.73 | CNR1 (0.41) | HTTCNR1CNR2POLBKMT2A | |
| SCHEMBL5171818 | 0.73 | CNR1 (0.44) | HTTCNR1CNR2POLBLMNA | |
| SCHEMBL4931772 | 0.73 | MAPK1 (0.50) | HTTPOLBKMT2ALMNA | |
| SCHEMBL4934649 | 0.72 | NAMPT (0.48) | HTTCNR1POLBKMT2ALMNA | |
| SCHEMBL2827013 | 0.70 | MEN1 (0.60) | HTTKMT2ALMNA | |
| SCHEMBL9629234 | 0.70 | HTT (0.41) | HTTCNR1CNR2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | claimed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | claimed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167309-A1 | Pharmaceutical Compounds | CCNO, CDK2, CDK1 | HTT 829/4885MAPK8 390/4885MAPK10 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.